ArticleInfection & chemotherapy2026
Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial.
Article in Infection & chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04886596 (A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) poses substantial health risks to elderly adults and adults with certain underlying conditions. In a multi-country phase 3 trial (AReSVi-006), the adjuvanted RSVPreF3 vaccine has shown high efficacy against RSV disease. This post-hoc sub-analysis assessed immunogenicity, immunopersistence up to 24 months, and safety of a single dose of the adjuvanted RSVPreF3 vaccine in the Korean cohort. MATERIALS AND
methodsIn the global, randomized, observer-blind, placebo-controlled phase 3 trial (NCT04886596), adults ≥60 years of age were randomized 1:1 to receive a single intramuscular dose of the adjuvanted RSVPreF3 vaccine or placebo. The Korean cohort (12 sites) included 719 participants. Immunogenicity and reactogenicity were evaluated in a subset of participants. Safety data included solicited adverse events (AEs) within four days, unsolicited AEs up to 30 days, and serious adverse events (SAEs)/potential immune-mediated diseases up to six months post-vaccination.
resultsIn the Korean cohort, 360 participants received the adjuvanted RSVPreF3 vaccine and 359 received placebo; 91 were included in the solicited safety set and 87 in the per-protocol immunogenicity set. By Day 31, neutralizing titers had increased robustly in the RSVPreF3 group with a mean geometric increase (MGI) versus baseline of 7.7 (RSV-A) and 7.2 (RSV-B); RSVPreF3-binding IgG concentrations showed an MGI of 13.4 in the RSVPreF3 group. Reactogenicity was mostly mild; solicited administration-site AEs occurred in 58.7% (predominantly pain) and solicited systemic AEs in 60.9% (predominantly fatigue) of participants in the RSVPreF3 group; no vaccine-related SAEs were reported. RSV-A and RSV-B neutralizing titers and RSVPreF3-binding IgG concentrations remained above baseline until 24 months post-vaccination, with an MGI of 2.2 (RSV-A), 1.3 (RSV-B), and 2.7 (RSVPreF3-binding IgG).
conclusionIn Korean adults aged ≥60 years, a single dose of the adjuvanted RSVPreF3 vaccine elicited a robust immune response, which persisted for up to 24 months post-vaccination, with an acceptable safety profile.
trial registrationClinicalTrials.gov Identifier: NCT04886596.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.